Faeth Therapeutics is a cancer metabolism company developing clinically-tested nutrition control, therapeutics, and digital tools for the treatment of cancer.
Faeth's mission is to help every cancer patient use the power inside them to beat their cancer with world-leading science and precision nutrition.
Faeth was founded in 2019 by Anand Parikh, Lew Cantley, Scott Lowe, Siddhartha Mukherjee, Greg Hannon, and Karen Vousden. The company is headquartered in San Francisco, CA.
Faeth uses metabolism and precision nutrition to starve cancer of the nutrients it needs to grow and resist treatment has the potential to transform the efficacy of conventional cancer therapies.
The Faeth Program is highly personalized precision nutrition designed to deprive tumors of the nutrients they needs to grow, while providing optimal nutritional support to healthy tissues.
Faeth's research, published in peer-reviewed scientific journals, shows that tailoring the right diet to the cancer patient can significantly impact the efficacy of clinically tested therapeutics for cancer. It has now moved to first-in-human clinical trials looking at pancreatic, colon, endometrial and ovarian cancers.
Faeth is backed by S2G Ventures, Khosla Ventures, Future Ventures, Digitalis, KdT Ventures, AgFunder, Cantos, and others. The company closed its Series A round with $47M on Jun 30, 2022. This brings Faeth's total funding to $67M to date.